|Table of Contents|

Treatment options and prognostic factors of newly diagnosed ALL in children and adolescents over 10 years old

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 01
Page:
134-139
Research Field:
Publishing date:

Info

Title:
Treatment options and prognostic factors of newly diagnosed ALL in children and adolescents over 10 years old
Author(s):
JIN Shengxian; LI Dan; GAO Yu; ZHANG Xian
Department of Pediatric Hematology Oncology,Women's and Children's Central Hospital of Chengdu，Sichuan Chengdu 610091,China.
Keywords:
children; adolescents; ALL; clinical effects; prognosis; influencing factors
PACS:
R733
DOI:
10.3969/j.issn.1672-4992.2023.01.025
Abstract:
Objective:To investigate the treatment options and prognostic factors of newly diagnosed ALL in children and adolescents over 10 years old.Methods:119 newly diagnosed ALL children with over 10 years old and adolescents were retrospectively chosen in the period from January 2008 to December 2015.The baseline clinical characteristics,remission effect of induction therapy,clincial efficacy for long-term,recurrence rate and mortality were analyzed,and the influencing factors of clinical prognosis were evaluated by univariate and multivariate analysis.Results:There was no significant difference in the proportion of complete remission at the 35 d after induction therapy between ALL-2005 and ALL-2009 regimens（P＞0.05）.The cumulative event-free survival rate and total survival rate of 119 children in 5-year with follow-up were separately （64.51±3.75）%，（69.85±4.11）% and in 7-year with follow-up were separately （62.96±3.82）%，（68.12±3.69）%.There was no significant difference in cumulative event-free survival rate,overall survival rate,total recurrence rate,extramedullary recurrence rate,recurrence time and survival rate between ALL-2005 and ALL-2009 regimens（P＞0.05）.The survival rate of extramedullary recurrence group were significantly higher than bone marrow recurrence group（P＜0.05）.The survival rate of recurrence in late period group were significantly higher than that recurrence in early period group（P＜0.05）.There was no significant difference in mortality between ALL-2005 and ALL-2009 regimens（P＞0.05）.Univariate analysis showed that age,gender,induction therapy,risk and fusion gene were correlated with clinical prognosis（P＜0.05）.Multivariate analysis showed that male,fusion gene,unremitted induction therapy and high risk were the independent risk factors for poor prognosis in children（P＜0.05）.The survival rate of children with BCR-ABL(+) by ALL-2009 regimen were significantly higher than ALL-2005 regimen（P＜0.05）.The event free survival rate in 5-year with follow-up of middle-risk children treated with two kinds regimens were significantly higher than high-risk children（P＜0.05）.The event free survival rate in 5-year follow-up of children with B-line ALL by ALL-2009 regimen were significantly higher than T-line（P＜0.05）.Conclusion:The survival rate of newly diagnose ALL children over 10 years old and adolescents treated with ALL-2009 program are suitable for the population with BCR-ABL(+) and gender,fusion gene,induction therapy effect and risk are closely related to the clinical prognosis of children above.

References:

［1］TAKAHASHI H,KAJIWARA R,KATO M,et al.Treatment outcome of children with acute lymphoblastic leukemia:the Tokyo Children's Cancer Study Group(TCCSG) Study L04-16［J］.Int J Hematol,2018,108(1):98-108.
［2］SANDART A,HARILA-SAARI A,ARNELL H,et al.Pattern and prevalence of liver involvement in pediatric acute lymphoblastic and myeloid leukemia at diagnosis［J］.J Pediatr Gastroenterol Nutr,2021,20(7):814-820.
［3］RODRIGUEZ-WALLBERG KA,MILENKOVIC M,PAPAIKONOMOU K,et al.Successful pregnancies after transplantation of ovarian tissue retrieved and cryopreserved at time of childhood acute lymphoblastic leukemia-A case report［J］.Haematologica,2021,8(7):2178-2185.
［4］蔡娇阳,王宁玲,蒋慧,等.儿童急性淋巴细胞白血病2005方案多中心远期临床报告［J］.中华儿科杂志,2018,56(7):511-517. CAI JY,WANG NL,JIANG H,et al.Multicenter long-term clinical report of acute lymphoblastic leukemia in children 2005［J］.Chin J Pediat,2018,56(7):511-517.
［5］中华医学会儿科学分会.儿科血液系统疾病诊疗规范［M］.北京:人民卫生出版社,2014:267-268. Scientific Branch of Chinese Medical Association.Diagnosis and treatment of pediatric hematological diseases［M］.Beijing:People's Health Publishing House,2014:267-268.
［6］王建祥.血液病诊疗规范［M］.北京:中国协和医科大学出版社,2014:127-128. WANG JX.Blood disease diagnosis and treatment standard［M］.Beijing:China Union Medical University Press,2014:127-128.
［7］PORDANJANI SR,KAVOUSI A,MIRBAGHERI B,et al.Spatial analysis and geoclimatic factors associated with the incidence of acute lymphoblastic leukemia in Iran during 2006-2014:An environmental epidemiological study［J］.Environ Res,2021,14(7):111662.
［8］VROOMAN LM,BLONQUIST TM,STEVENSON KE,et al.Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia:Results of DFCI 11-001［J］.J Clin Oncol,2021,6(7):3692-3699.
［9］MCNEER JL,BLEYER A.Acute lymphoblastic leukemia and lymphoblastic lymphoma in adolescents and young adults［J］.Pediat Blood Cancer,2018,65(1):e26989.
［10］BARR RD,INGLIS D,ATHALE U,et al.Bone health in long-term survivors of pediatric acute lymphoblastic leukemia.An assessment by peripheral quantitative computed tomography［J］.Pediatr Blood Cancer,2021,15(7):e29218.
［11］STOCK W,LUGER SM,ADBANI AS,et al.A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia:results of CALGB 10403［J］.Blood,2019,133(14):1548-1559.
［12］NICOLAS B,BARUCHEL A.Acute lymphoblastic leukemia in adolescent and young adults:treat as adults or as children［J］.Blood,2018,132(4):351-361.
［13］YAMAZOE T,AKAGAWA S,MATSUNO R,et al.Superiority of cystatin C over creatinine for early diagnosis of acute kidney injury in pediatric acute lymphoblastic leukemia/lymphoblastic lymphoma［J］.Tohoku J Exp Med,2021,254(3):163-170.
［14］CHEN H,WANG XJ,YUAN FF,et al.Expression and clinical significance of Ki-67 in adult and children with acute lymphoblastic leukemia［J］.Chin J Exp Hematol,2018,26(1):70-76.
［15］LILLIE K.Leukaemia and lockdown:The delayed infection model of childhood acute lymphoblastic leukaemia and the COVID-19 pandemic［J］.Pediatr Blood Cancer,2021,12(7):e29194.
［16］KAMODA Y,IZUMI K,IIOKA F,et al.Philadelphia chromosome-positive acute lymphoblastic leukemia is separated into two subgroups associated with survival by BCR-ABL fluorescence in situ hybridization of segmented cell nuclei:report from a single institution［J］.Acta Haematol,2016,136(3):157-166.
［17］FUJISAWA S,MIZUTA S,AKIYAMA H,et al.Phase Ⅱ study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia［J］.Am J Hematol,2017,92(4):367-374.
［18］FUJIMAKI K,HATTORI Y,NAKAJIMA H.10-year complete remission in a philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation［J］.Int J Hematol,2018,107(6):709-711.
［19］JEHA S,CHOI J,ROBERTS KG,et al.Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy［J］.Blood Cancer Discov,2021,2(4):326-337.
［20］CAZZANIGA G,DE LORENZO P,ALTEN J,et al.Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of philadelphia-chromosome-positive acute lymphoblastic leukemi［J］.Haematologica,2018,103(1):107-115.
［21］MAHNOOD N,ABBAS SN,NAZEER QUA,et al.Molecular detection of hupB gene of mycobacterium tuberculosis in young patients with acute lymphoblastic leukemia(ALL) on chemotherapy［J］.Pak J Pharm Sci,2020,33(5):2471-2475.
［22］CHOI HJ,SHIN J,KANG S,et al.Long-term treatment outcomes of children and adolescents with lymphoblastic lymphoma treated with various regimens:a single-center analysis［J］.Blood Res,2020,55(4):262-274.

Memo

Memo:
-
Last Update: 2022-11-30